详情页 - 河北大学附属医院知识库

资源类型：

文章类型：

作者：

Zhang, Lina[1] * ; Geng, Cuizhi[2] ; Liu, Yueping[1] ; Han, Jianjun[3] ; Han, Meng[4] ; Huang, Ruixue[5] ; Li, Xianqiao[3] ; Luo, Ruizhen[6] ; Li, Yuntao[1] ; Ma, Jie[7] ; Qi, Huaihua[8] ; Wang, Zunyi[9] ; Wang, Xiaochun[10]

; Yang, Chao[1] ; Yang, Jingqiang[11] ; Yang, Lixian[12] ; Yu, Jingjing[13] ; Zhang, Yingzhou[14] ; Zhang, Zhisheng[15] ; Zhou, Xinping[14] ;

机构： [1]The Fourth Hospital of Hebei Medical University, Shijiazhuang, China [2]Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China [3]Affiliated Hospital of Hebei Engineering University, Handan, China [4]First Hospital of Qinhuangdao, Qinhuangdao, China [5]Qinhuangdao Maternal and Child Health Hospital, Qinhuangdao, China [6]Department of Breast Surgery, Cangzhou Hospital of Integrated TCM-WM Hebei, Cangzhou, China [7]Department of Breast Surgery, Tangshan People's Hospital, Tangshan, China [8]Tangshan People's Hospital, Tangshan, China [9]Cangzhou Central Hospital, Cangzhou, China [10]Affiliated Hospital of Hebei University, Baoding, China [11]Hengshui Harrison International Peace Hospital, Hengshui, China [12]Xingtai People’s Hospital, Xingtai, China [13]Xingtai Central Hospital, Xingtai, China [14]Handan Central Hospital, Handan, China [15]The First Affiliated Hospital of Hebei North University, Zhangjiakou, China

出处：

ISSN：

语种：

WOS：

中科院(CAS)分区：

出版当年[2025]版：

无

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2024]版：

无

最新[2023]版：

Q1 ONCOLOGY

第一作者：

第一作者机构： [1]The Fourth Hospital of Hebei Medical University, Shijiazhuang, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

A phase II trial comparing dalpiciclib in combination with letrozole versus standard chemotherapy as neoadjuvant therapy in patients with high-risk HR- positive HER-2 negative breast cancer: DARLING-02

文献详情